|
The Next Frontier: Generative AI in Pharma and Legal Considerations
Webinar
| 
ACMA is accredited, trusted, and reliable
This webinar is not just another discussion on AI; it's a targeted exploration of generative AI in the pharmaceutical industry and the related compliance and legal concerns. Their presentations will not only highlight the potential of AI to revolutionize the industry but also address the ethical, legal, and regulatory frameworks necessary for its successful and responsible implementation.
$9.99
Get access to full webinar slide deck
Topics covered in webinar
- Key Innovations and Impact of Generative AI in Pharma
- Generative AI Use Cases Across Pharma Sectors
- Navigating the Hype vs. Reality of Generative AI
- Ethical and Regulatory Considerations in AI Adoption
Webinar Speakers
Leaders in the pharmaceutical industry
D
Dr. William Soliman
PhD, BCMAS
The Founder and CEO of the Accreditation Council for Medical Affairs (ACMA), brings over 15 years of senior executive experience in the pharmaceutical and life sciences industries to our panel. Dr. Soliman is a respected voice in medical affairs, frequently featured in media outlets such as Fox News, Forbes, Al Jazeera, Yahoo Business TV, and ABC News Radio. His session will delve into the key innovations and impact of generative AI in pharma, alongside real-world use cases that are driving the sector forward
A
Alex Shandro
Senior Associate at Allen & Overy
a renowned advisor in transactional IP and complex commercial contracts with a focus on AI, brings a wealth of knowledge, especially in the life sciences and technology sectors. Specializing in the legal challenges and opportunities presented by AI, Alex is currently guiding over 70 clients, including numerous pharmaceutical companies, on the safe deployment of generative AI. His expertise encompasses mitigating IP and data risks, contract terms, and AI drug discovery collaborations. Alex's session will provide essential insights into navigating the legal and regulatory considerations essential for AI adoption in the pharmaceutical industry.